The anticoagulant apixaban performed comparably with the standard treatment warfarin in a trial involving 5,395 patients with acute venous thromboembolism, according to findings published in the New England Journal of Medicine. The new drug reduced the risk of major bleeding by around 70% and clinically relevant non-major bleeding by more than 50%, the study said. The AMPLIFY trial randomized the patients to either conventional therapy with enoxaparin and warfarin or apixaban. The findings "add to the evidence that the new oral anticoagulants are simple alternatives to conventional therapy for patients with acute venous thromboembolism," researchers wrote.
Published in Brief: